Developing an artificial intelligence-guided signal detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A proof-of-concept study using galcanezumab and simulated data.

Fahed Al-Azzawi[1], Israa Mahmoud[1], François Haguinet[2], Andrew Bate[3,4,5], Maurizio Sessa[1]

[1] Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

[2] GSK, Wavre, Belgium

[3] GSK, London, UK

[4]London School of Hygiene and Tropical Medicine, University of London, London, UK

[5]New York University, New York, NY, USA

Journal: Drug Safety.

Corresponding author

Fahed Al-Azzawi, MPharm
Department of Drug Design and Pharmacology,
University of Copenhagen,
Jagtvej 160Copenhagen 2100, Denmark
Email: kdz640@sund.ku.dk



Electronic supplementary material 2. Sensitivity analysis.